Study of Azeliragon in Patients With Mild Alzheimer's Disease and Impaired Glucose Tolerance

Inclusion Criteria: * Diagnosis of probable Alzheimer Disease (AD) with documented evidence of progression of disease * Mini Mental State Examination (MMSE) score of 21-26, inclusive * Clinical Dementia Rating global score of 0.5 or 1 * Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog14) of 10 or more * Brain magnetic resonance imaging (MRI) consistent with the diagnosis of probable AD * Concurrent use of cholinesterase inhibitor or memantine with stable dose for at least 2 months prior to screening * Hemoglobin A1c (HbA1c) 6.5% - 9.5%, inclusive * Caregiver willing to participate and be able to attend clinic visits with patient * Ability to ingest oral medications Exclusion Criteria: * Significant neurological or psychiatric disease other than Alzheimer's disease * Previous clinical trial participation within 90 days of screening * Previous exposure to putative disease modifying therapy for Alzheimer's disease within 1 year of screening * History of cancer within the last 5 years except adequately treated cervical carcinoma in-situ, cutaneous basal cell or squamous cell cancer, or non-progressive prostate cancer not requiring current treatment * Women of childbearing potential * Uncontrolled blood pressure and/or blood pressure above 140/90 * Participants receiving medications that may negatively impact cognitive function * History of diabetic ketoacidosis within the past year * History of chronic pancreatitis * Stage 4 kidney disease * Use of insulin therapy